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(57) ABSTRACT 
The presently-disclosed subject matter provides biosensors 
for detecting molecules of interest. The biosensors include a 
polypeptide capable of selectively-binding glucose, Wherein 
the polypeptide molecule is selected from: an unnatural ana 
logue of Wildtype glucose binding protein; a fragment of Wild 
type glucose binding protein; and an unnatural analogue frag 
ment of Wild type glucose binding protein. 
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POLYPEPTIDES, SYSTEMS, AND METHODS 
USEFUL FOR DETECTING GLUCOSE 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Application Ser. Nos. 60/954,269 ?led on Aug. 6, 2007, and 
60/954,348 ?led on Aug. 7, 2007, the entire disclosures of 
Which are incorporated herein by this reference. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to biosen 
sors, and systems and methods useful for detecting glucose. 
BACKGROUND 
Monitoring blood glucose levels in a diabetic individual is 
important for maintaining metabolic control in the individual. 
Currently-available systems and methods of monitoring glu 
cose levels require extraction of blood from the diabetic indi 
vidual at multiple times during each day, e.g., ?nger prick. As 
such, only information about blood glucose levels at discrete 
time points is made available. Additionally, extracting blood 
for use in testing can be painful, and as a result, can lead to loW 
compliance or non-compliance by diabetic individuals. 
Efforts have therefore been made to develop an effective 
system and method for monitoring blood glucose levels in a 
continuous and less invasive manner. Biosensors have been 
proposed for use in the in vivo, continuous detection of blood 
analyte levels. A biosensor includes an element capable of 
speci?cally detecting an analyte of interest, alloWing a mea 
surable signal to be produced, Which can be correlated to 
analyte concentration. 
Biosensors for detecting glucose can include an element 
that selectively binds glucose. For example, Wild type glucose 
binding protein (WtGBP) is capable of binding glucose. GBP 
of Escherichia coli is a 33 kDa periplasmic binding protein. 
GBP consists of tWo distinctly similarly folded globular 
domains that are connected to each other by three peptide 
segments. The sugar binding site is located in the cleft of the 
protein formed betWeen the tWo domains. The binding of 
glucose is accompanied by a conformational change of the 
protein at the hinge region. In the open form of GBP (in the 
absence of glucose) the tWo domains are far apart and the cleft 
is exposed to the solvent, While in the closed form the glucose 
is engulfed in the cleft. 
Although biosensors have made use of certain WtGBPs, 
such biosensors have drawbacks. For example, GBPs are not 
very stable at room temperature. As such, there are apparent 
problems associated biosensors that make use of WtGBP for 
monitoring blood glucose levels in diabetic patients. Further 
more, currently-available systems and methods for continu 
ously-detecting glucose are associated With a signi?cant 
inability to detect glucose levels in the hypoglycemic ranges 
in a reliable manner. Further, these available systems also 
suffer from short lifespans and are not easily used for routine 
clinical use. In addition, the use of current WtGBPs for con 
tinuous blood glucose monitoring for implantable or catheter 
based devices is complicated by the need for sterilization. The 
development of novel proteins With improved thermal and 
chemical stability Will lead to easier and more cost-effective 
means of sterilization. 
Accordingly, there is a need in the art for systems and 
methods for detecting glucose levels in a subject in a continu 
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2 
ous manner, at ambient temperatures, With operability for 
clinical use, reliability, speci?city, and sensitivity. 
SUMMARY 
The presently-disclosed subject matter meets some or all of 
the above-identi?ed needs, as Will become evident to those of 
ordinary skill in the art after a study of information provided 
in this document. 
This Summary describes several embodiments of the pres 
ently-disclosed subject matter, and in many cases lists varia 
tions and permutations of these embodiments. This Summary 
is merely exemplary of the numerous and varied embodi 
ments. Mention of one or more representative features of a 
given embodiment is likeWise exemplary. Such an embodi 
ment can typically exist With or Without the feature(s) men 
tioned; likeWise, those features can be applied to other 
embodiments of the presently-disclosed subject matter, 
Whether listed in this Summary or not. To avoid excessive 
repetition, this Summary does not list or suggest all possible 
combinations of such features. 
The presently-disclosed subject matter provides, in some 
embodiments, a biosensor for detecting a molecule of inter 
est. In some embodiments, the biosensor comprises an iso 
lated polypeptide molecule capable of selectively-binding 
glucose. In some embodiments, the polypeptide molecule is 
selected from: an unnatural analogue of Wild type glucose 
binding protein; a fragment of Wild type glucose binding 
protein; and an unnatural analogue fragment of Wild type 
glucose binding protein. The biosensor further comprises a 
label associated With the polypeptide molecule, Wherein 
binding of glucose to the polypeptide molecule causes the 
label to generate a signal, such that the glucose can be 
detected. 
In some embodiments, the polypeptide molecule is a frag 
ment of Wild type glucose binding protein. In some embodi 
ments, the polypeptide molecule is a fragment of the amino 
acid sequence of SEQ ID NO: 1, Wherein up to about 13 
amino acids are truncated from the N-terminus and/or 
Wherein up to about 83 amino acids are truncated from the 
C-terminus of SEQ ID NO: 1. In some embodiments, the 
polypeptide molecule is a fragment of the amino acid 
sequence of SEQ ID NO: 5, Wherein up to about 12 amino 
acids are truncated from the N-terminus and/ or Wherein about 
99 amino acids are truncated from the C-terminus of SEQ ID 
NO: 5. In some embodiments, the polypeptide molecule, 
comprises the amino acid sequence of SEQ ID NOs: 1-7. 
In some embodiments, the polypeptide molecule is an 
unnatural analogue of Wild type glucose binding protein, 
Wherein one or more natural amino acids of Wild type glucose 
binding protein are replaced With one or more unnatural 
amino acids. In some embodiments, the one or more natural 
amino acids of Wild type glucose binding protein are replaced 
With one or more unnatural amino acids as set forth in Table 
A. In some embodiments, the polypeptide molecule is an 
unnatural analogue or an unnatural analogue fragment, 
Wherein one or more natural leucines are replaced With 
unnatural leucines. In some embodiments, one or more natu 
ral leucines are replaced With 5,5,5-tri?uoroleucine. In some 
embodiments, one or more natural leucines are replaced With 
5,5,5-tri?uoro-DL-leucine. In some embodiments, one or 
more natural tryptophans are replaced With 5-?uorotryp 
tophan. In some embodiments, one or more natural tryp 
tophans are replaced With 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule is stable 
over a Wider range of temperatures relative to WtGBP. In some 
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embodiments, the polypeptide molecule is stable at tempera 
tures betWeen about 55° C. and about 75° C. 
In some embodiments, the label is a ?uorophore. In some 
embodiments, label is the ?uorophore MDCC. In some 
embodiments, binding of glucose to the polypeptide mol 
ecule causes the label to generate a detectably altered ?uo 
rescence intensity of the ?uorophore such that the glucose can 
be detected. In some embodiments, the ?uorescence intensity 
can be correlated to the concentration of the glucose in a 
sample. 
In some embodiments, the label is attached to an amino 
acid site of the polypeptide molecule selected from Asp 13, 
Asp 44, Val 68, Ala 71, Phe 90, Lys 92, Glu 93, Pro 94, Lys 
97,Gly 109, Thr 110,Asp 111,Gly 151, Pro 153,Ala 155,Asp 
184, Asp 212, Leu 255, Ala 258,Asn 260, Ala 262, Arg 292, 
Val 293, and Pro 294. 
In some embodiments of the presently-disclosed subject 
matter, a method for detecting a glucose molecule is pro 
vided. In some embodiments, the method comprises contact 
ing a biosensor disclosed herein With a sample of interest; 
detecting the signal; and collecting and displaying the signal 
With a detection and data collection device, to thereby detect 
the glucose. In some embodiments, the glucose is continu 
ously detected. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1A is a rendering of the three-dimensional structure of 
the polypeptide of SEQ ID NO: 1. The 3D structures Were 
created using a protein structure modeling program called DS 
VieWer Pro. Structural information for proteins is available 
online through the RCSB Protein Data Bank. This structural 
information is available in the form of a ?le that contains the 
coordinates in three dimensions for proteins such as they have 
been published in current literature sources. Protein structure 
?les are available by PDB#. In this document, the PDB ?les 
used are as folloWs: #1GLG(WtGBP fromE. cali) and #2H3H 
(WtGBP from T marilima), FIG. 1A and FIG. 2A, respec 
tively. 
FIG. 1B is a rendering of the three-dimensional structure of 
the polypeptide of SEQ ID NO: 2. The structure shoWn is a 
truncated form of the complete WtGBP from E. coli shoWn in 
FIG. 1A, in Which the dark gray portion represents the struc 
ture of the truncated form speci?ed by the ?gure and the light 
gray portion represents the portion of the WtGBP that is being 
omitted. 
FIG. 1C is a rendering of the three-dimensional structure of 
the polypeptide of SEQ ID NO: 3. The structure shoWn is a 
truncated form of the complete WtGBP from E. coli shoWn in 
FIG. 1A, in Which the dark gray portion represents the struc 
ture of the truncated form speci?ed by the ?gure and the light 
gray portion represents the portion of the WtGBP that is being 
omitted. 
FIG. 1D is a rendering of the three-dimensional structure of 
the polypeptide of SEQ ID NO: 4. The structure shoWn is a 
truncated form of the complete WtGBP from E. coli shoWn in 
FIG. 1A, in Which the dark gray portion represents the struc 
ture of the truncated form speci?ed by the ?gure and the light 
gray portion represents the portion of the WtGBP that is being 
omitted. 
FIG. 2A is a rendering of the three-dimensional structure of 
the polypeptide of SEQ ID NO: 5. The 3D structures Were 
created using DS VieWer Pro. 
FIG. 2B is a rendering of the three-dimensional structure of 
the polypeptide of SEQ ID NO: 6. The structure shoWn is a 
truncated form of the complete WtGBP from T maritime 
shoWn in FIG. 2A, in Which the dark gray portion represents 
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4 
the structure of the truncated form speci?ed by the ?gure and 
the light gray portion represents the portion of the WtGBP that 
is being omitted. 
FIG. 2C is a rendering of the three-dimensional structure of 
the polypeptide of SEQ ID NO: 7. The structure shoWn is a 
truncated form of the complete WtGBP from T maritime 
shoWn in FIG. 2A, in Which the dark gray portion represents 
the structure of the truncated form speci?ed by the ?gure and 
the light gray portion represents the portion of the WtGBP that 
is being omitted. 
FIG. 3 is a dose response curve for glucose With an unnatu 
ral analogue of a WtGBP, including the isolated polypeptide 
of SEQ ID NO: 1, Where natural tryptophans are replaced 
With 5 -?uorotryptophans; 
FIG. 4 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP, including the isolated 
polypeptide of SEQ ID NO: 2, Where natural tryptophans are 
replaced With 5-?uorotryptophans; 
FIG. 5 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP, including the isolated 
polypeptide of SEQ ID NO: 3, Where natural tryptophans are 
replaced With 5-?uorotryptophans; 
FIG. 6 is a dose response curve for glucose With an unnatu 
ral analogue of a WtGBP, including the isolated polypeptide 
of SEQ ID NO: 1, Where natural leucines are replaced With 
5,5,5-tri?uoroleucines; 
FIG. 7 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP, including the isolated 
polypeptide of SEQ ID NO: 2, Where natural leucines are 
replaced With 5,5,5-tri?uoroleucines; 
FIG. 8 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP, including the isolated 
polypeptide of SEQ ID NO: 3, Where natural leucines are 
replaced With 5,5,5-tri?uoroleucines; 
FIG. 9 is a dose response curve for glucose With an unnatu 
ral analogue of WtGBP including unnatural tryptophan, 
immobiliZed on a ?ber optic tip; 
FIG. 10 is a circular dichroism (CD) spectrum of an 
unnatural analogue of a WtGBP, including the isolated 
polypeptide of SEQ ID NO: 2, Where natural leucines are 
replaced With 5,5,5-tri?uoroleucines; and 
FIG. 11 is a CD spectrum of a WtGBP, including the iso 
lated polypeptide of SEQ ID NO: 1. 
FIG. 12 are tWo graphs shoWing a comparison of the ?uo 
rescence emission intensity of GBP and GRP-7-AZatryp 
tophan. 
FIG. 13 is a CD spectrum shoWing a comparison of the 
?uorescence emission intensity over a range of temperatures 
of GRP-7-AZatryptophan Without (light grey line) or With 
(dark grey line, shifted right toWard higher temperature) 
bound glucose. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1 includes an amino acid sequence for Wild 
type glucose binding protein (WtGBP) from Escherichia coli 
(GenBank Accession number X05646). The disclosed 
sequence provided is Without the N-terminal signaling pep 
tide. 
SEQ ID NO: 2 includes an amino acid sequence for tGBPl, 
including amino acids 14-296 of SEQ ID NO: 1. 
SEQ ID NO: 3 includes an amino acid sequence for tGBP2, 
including amino acids 14-256 of SEQ ID NO: 1. 
SEQ ID NO: 4 includes an amino acid sequence for tGBP3, 
including amino acids 14-226 of SEQ ID NO: 1. 
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SEQ ID NO: 5 includes an amino acid sequence for Wild 
type glucose binding protein (WtGBP) from Thermologa 
marilima (GenBank® Accession No. NPi227930), Where 
the ?rst 31 amino acids making up the N-terminal signaling 
peptide have been removed. 
SEQ ID NO: 6 includes an amino acid sequence for tGRP4, 
including amino acids 13-253 of SEQ ID NO: 5. 
SEQ ID NO: 7 includes an amino acid sequence for tGRP5, 
including amino acids 13-205 of SEQ ID NO: 5. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently 
disclosed subject matter are set forth in this document. Modi 
?cations to embodiments described in this document, and 
other embodiments, Will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the speci?c details of the described exemplary 
embodiments, is provided primarily for cleamess of under 
standing and no unnecessary limitations are to be understood 
therefrom. 
Some of the polynucleotide and polypeptide sequences 
disclosed herein are cross-referenced to GENBANK® acces 
sion numbers. The sequences cross-referenced in the GEN 
BANK® database are expressly incorporated by reference as 
are equivalent and related sequences present in GENBANK® 
or other public databases. Also expressly incorporated herein 
by reference are all annotations present in the GENBANK® 
database associated With the sequences disclosed herein. 
While the folloWing terms are believed to be Well under 
stood by one of ordinary skill in the art, the folloWing de?ni 
tions are set forth to facilitate explanation of the presently 
disclosed subject matter. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to Which the presently 
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently 
disclosed subject matter, representative methods, devices, 
and materials are noW described. 
Following long-standing patent laW convention, the terms 
“a”, “an”, and “the” refer to “one or more” When used in this 
application, including the claims. Thus, for example, refer 
ence to “a cell” includes a plurality of such cells, and so forth. 
Unless otherWise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the speci?cation and claims are to be 
understood as being modi?ed in all instances by the term 
“about”. Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this speci?cation and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term “about,” When referring to a value 
or to an amount of mass, Weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments 120%, in some embodiments 110%, in some 
embodiments 15%, in some embodiments 11%, in some 
embodiments 10.5%, and in some embodiments 10.1% from 
the speci?ed amount, as such variations are appropriate to 
perform the disclosed method. 
The presently-disclosed subject matter includes isolated 
polypeptides useful for detecting glucose. The presently-dis 
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6 
closed subject matter further includes biosensors, systems, 
and methods for detecting glucose. 
The presently-disclosed subject matter includes isolated 
polypeptide molecules that are capable of selectively-binding 
glucose, and biosensors that include isolated polypeptide 
molecules that are capable of selectively-binding glucose. In 
some embodiments, the isolated polypeptide molecule is a 
fragment of a Wild type glucose binding protein (WtGBP). In 
some embodiments, the isolated polypeptide molecule is an 
unnatural analogue of WtGBP. In some embodiments, the 
isolated polypeptide molecule is an unnatural analogue frag 
ment of WtGBP. 
The terms “polypeptide, protein,” and “peptide,” Which 
are used interchangeably herein, refer to a polymer of the 20 
protein amino acids, including modi?ed amino acids (e.g., 
phosphorylated, glycated, etc.) and amino acid analogs, 
regardless of siZe or function. Although “protein” is often 
used in reference to relatively large polypeptides, and “pep 
tide” is oftenused in reference to small polypeptides, usage of 
these terms in the art overlaps and varies. The term “peptide” 
as used herein refers to peptides, polypeptides, proteins, and 
fragments of proteins, unless otherWise noted. The terms 
“protein”, “polypeptide”, and “peptide” are used inter 
changeably herein When referring to a gene product and frag 
ments thereof. Thus, exemplary polypeptides include gene 
products, naturally occurring proteins, homologs, orthologs, 
paralogs, fragments, and other equivalents, variants, frag 
ments, and analogs of the foregoing. In some embodiments, 
the term polypeptide includes a conservatively substituted 
variant. 
The term “conservatively substituted variant” refers to a 
peptide comprising an amino acid residue sequence that dif 
fers from a reference peptide by one or more conservative 
amino acid substitution, and maintains some or all of the 
activity of the reference peptide as described herein. A “con 
servative amino acid substitution” is a substitution of an 
amino acid residue With a functionally similar residue. 
Examples of conservative substitutions include the substitu 
tion of one non-polar (hydrophobic) residue such as isoleu 
cine, valine, leucine or methionine for another; the substitu 
tion of one polar (hydrophilic) residue for another such as 
betWeen arginine and lysine, betWeen glutamine and aspar 
agine, betWeen glycine and serine; the substitution of one 
basic residue such as lysine, arginine or histidine for another; 
or the substitution of one acidic residue, such as aspartic acid 
or glutamic acid for another. 
The term “isolated,” When used in the context of an isolated 
polypeptide, is a polypeptide that, by the hand of man, exists 
apart from its native environment and is therefore not a prod 
uct of nature. 
As used herein, the term “selectively-bind” refers to an 
interaction betWeen glucose and a binding site of a polypep 
tide molecule. In some embodiments, the interaction betWeen 
glucose and the binding site can be identi?ed as “selective” if: 
the equilibrium dissociation constant (K) is about the same 
or less than the Kd of glucose and a reference polypeptide 
binding site; the equilibrium inhibitor dissociation constant 
(K1) is about the same or less than the K- of glucose and a 
reference polypeptide binding site; or the effective concen 
tration at Whichbinding of glucose is inhibited by 50% (ECSO) 
is about the same or less than the EC5O of glucose and a 
reference polypeptide binding site. For example, glucose 
selectively binds an isolated polypeptide molecule that is a 
fragment, unnatural analogue, or unnatural analogue frag 
ment of Wild type Glucose Binding Protein (WtGBP) if the 
Kd, Ki, and/or EC5O is about the same or less than the Kd of 
glucose and WtGBP. 
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In some embodiments, the interaction between glucose and 
the binding site can be identi?ed as “selective” When the 
equilibrium dissociation constant (Kd) is less than about 100 
nM, 75 nM, 50 nM, 25 nM, 20 nM, 10 nM, 5 nM, or 2 nM. In 
some embodiments, the interaction betWeen glucose and the 
binding site can be identi?ed as “selective” When the equilib 
rium inhibitor dissociation constant (K) is less than about is 
less than about 100 11M, 75 11M, 50 11M, 25 11M, 20 11M, 10 11M, 
5 11M, or 2 11M, When competing With glucose. In some 
embodiments, the interaction betWeen glucose and the bind 
ing site can be identi?ed as “selective” When the effective 
concentration at Which glucose binding is inhibited by 50% 
(ECSO) is less than about 500 11M, 400 11M, 300 11M, 100 11M, 
50 11M, 25 11M, or 10 11M. 
The terms “polypeptide fragment” or “fragment”, When 
used in reference to a polypeptide, refers to a polypeptide in 
Which amino acid residues are absent as compared to the 
full-length reference polypeptide itself, but Where the remain 
ing amino acid sequence is usually identical to the corre 
sponding positions in the reference polypeptide. Such dele 
tions can occur at the amino-terminus or carboxy-terminus of 
the reference polypeptide, or alternatively both. A fragment 
can retain one or more of the biological activities of the 
reference polypeptide. In some embodiments, a fragment can 
comprise a domain or feature, and optionally additional 
amino acids on one or both sides of the domain or feature, 
Which additional amino acids can number from 5, 10, 15, 20, 
or more residues. 
As used herein, the term “unnatural analogue” refers to a 
polypeptide Wherein one or more natural amino acids are 
replaced With unnatural amino acids, relative to a reference 
polypeptide. Examples of unnatural amino acids are set forth 
in Table A, provided herein beloW. 
As used herein, the term “unnatural analogue fragment” 
refers to a polypeptide fragment Wherein one or more natural 
amino acids are replaced With unnatural amino acids, relative 
to a reference polypeptide. 
As used herein, WtGBP refers to a reference protein includ 
ing the amino acid residues of a full-length Wild type glucose 
binding protein. A full-length Wild type glucose binding pro 
tein Will be knoWn to those of ordinary skill in the art. Some 
embodiments of the polypeptide molecule of the presently 
disclosed subject matter can be described With reference to 
the amino acid residues of a WtGBP. In some embodiments, 
the WtGBP can be a full-length WtGBP from E. coli (Gen 
Bank® Accession No. X05646). In some embodiments, the 
WtGBP can be the polypeptide of SEQ ID NO: 1. In some 
embodiments, the WtGBP can be a full-length WtGBP from T 
marilima (GenBank® Accession No. NPi227930). In some 
embodiments, the WtGBP can be the polypeptide of SEQ ID 
NO: 5. In some embodiments, the WtGBP can be a full-length 
WtGBP from T hermus lhermophilus (GenBank® Accession 
No. YPi004303). 
In some embodiments of the presently-disclosed subject 
matter, the isolated polypeptide molecule is a fragment of 
WtGBP that selectively binds glucose. For example, in some 
embodiments, the polypeptide molecule comprises a frag 
ment of WtGBP from E. coli including amino acids 14-296, 
set forth in SEQ ID NO: 2 (referred to herein as tGBPl). For 
another example, in some embodiments, the polypeptide 
molecule comprises a fragment of WtGBP from E. coli 
including amino acids 14-256, set forth in SEQ ID NO: 3 
(referred to herein as tGBP2). For yet another example, in 
some embodiments, the polypeptide molecule comprises a 
fragment of WtGBP from E. coli including amino acids 
14-226, set forth in SEQ ID NO: 4 (referred to herein as 
tGBP3). For another example, in some embodiments, the 
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polypeptide molecule comprises a fragment of WtGBP from 
T marilima including amino acids 13-253, set forth in SEQ 
ID NO: 6 (referred to herein as tGBP4). For another example, 
in some embodiments, the polypeptide molecule comprises a 
fragment of WtGBP from T marilima including amino acids 
13-205, set forth in SEQ ID NO: 7 (referred to herein as 
tGBP5). 
It is contemplated that isolated polypeptide molecules of 
the presently-disclosed subject matter can be fragments and/ 
or unnatural analogues of WtGBP for various species, or an 
isolated polypeptide molecule having a three-dimensional 
structure that is suf?ciently similar to such a WtGBP or func 
tional fragment thereof, such that it is capable of speci?cally 
binding glucose. Three-dimensional structures of the isolated 
polypeptide molecules of SEQ ID NOS: 1-7 are provided in 
FIGS. 1A-2C. These 3D structures Were created using a pro 
tein structure modeling program called DS Viewer Pro. Struc 
tural information for proteins is available online through the 
RCSB Protein Data Bank. This structural information is 
available in the form of a ?le that contains the coordinates in 
three dimensions for proteins such as they have been pub 
lished in current literature sources. Protein structure ?les are 
available by PDB#. In the present context, the PDB ?les used 
are as folloWs: #IGLG (WtGBP from E. coli) and #2H3H 
(WtGBP from T marilima). These structures are shoWn in 
FIG. 1A and FIG. 2A respectively. Structures shoWn in FIG. 
1B, FIG. 1C, and FIG. ID are truncated forms of the complete 
WtGBP from E. coli shoWn in FIG. 1A in Which the dark gray 
portion represents the structure of the truncated form speci 
?ed by that ?gure and the light gray portion represents the 
portion of the WtGBP that is being omitted. Likewise, FIG. 2B 
and FIG. 2C represent truncated forms of the complete 
WtGBP from T maritime shoWn in FIG. 2A in Which the dark 
gray portion represents the structure of the truncated form 
speci?ed by that ?gure and the light gray portion represents 
the portion of the WtGBP that is being omitted. 
In some embodiments, the polypeptide molecule of the 
presently-disclosed subject matter comprises a fragment of 
WtGBP, Whereinup to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids are 
truncated from the N-terminus of the WtGBP. In some 
embodiments, the polypeptide molecule comprises a frag 
ment ofWtGBP, Wherein up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 
96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 
109, or 1 10 amino acids are truncated from the C-terminus of 
WtGBP. 
Without Wishing to be bound by theory, it is believed that 
certain amino acids are useful for enhancing functionality of 
fragments of WtBGP provided from particular species. For 
example, amino acids 14,91, 152, 158, 211, 236, and 256 of 
WtGBP from E. coli (SEQ ID NO: 1) are believed to be 
involved in the binding of glucose. As such, in some embodi 
ments, the isolated polypeptide molecule is a fragment of 
WtGBP from E. coli (SEQ ID NO: 1) that includes amino 
acids 14, 91, 152, 158, 211, 236, and 256. In some embodi 
ments, the isolated polypeptide molecule is a fragment of 
WtGBP from E. coli (SEQ ID NO: 1) that includes at least 1, 
2, 3, 4, 5, or 6 of the amino acids selected from amino acids 
14, 91, 152, 158, 211, 236, and 256. Similarly, amino acid 13 
ofWtGBP from T marilima (SEQ ID NO: 5) is believed to be 
involved in the binding of glucose. As such, in some embodi 
US 8,465,981 B2 
ments, the isolated polypeptide molecule is a fragment of 
WtGBP from T marilima (SEQ ID NO: 5) that includes amino 
acid 13. 
In some embodiments of the presently-disclosed subject 
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polypeptide molecule comprises the sequence of WtGBP, 
Wherein one or more natural amino acids are replaced With 
one or more unnatural amino acids set forth in Table A. In 
some embodiments, the WtGBP can be from E. coli. In some 
matter, the isolated polypeptide molecule is an unnatural 5 embodiments, the WtGBP can be from T marilima. In some 
analogue of WtGBP. For example, in some embodiments, the embodiments, the WtGBP can be from T lhermophilus. 
TABLE A 
Structure of 
Natural Amino Acid Unnatural Amino Acid Unnatural Amino Acid 
Alanine 2-Pyridylalanine 
Alanine 3-Pyridylalanine — 
N\ / 
HZN 
OH 
O 
Alanine 4-Pyridylalanine 
Alanine p-Iodophenylalanine I 
HZN 
OH 
O 
Alanine p-Brornophenylalanine Br 
HZN 
OH 
US 8,465 ,981 B2 
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TABLE A-continued 
Sttucture of 
Natural Arnino Acid Unnatural Arnino Acid Unnatural AIHlHO Acid 
Alanine L-2-Arninobutyric acid H NH; 
H3C on 
“I” 
O 
Glycine L-Allylglycine / 
O 
HZN 
OH 
Glycine L-Propargylglycine % 
O 
HZN 
Glycine 2-Methoxy-phenylglycine 
0/ 
OH 
HZN 
O 
Glycine 3-Thienylglycine / S 
OH 
HZN 
O 
Leucine 5,5,5-trifluoro-DL-leucine C133 
0%} O I 
Lysine D-Lysine HZN H O 
H2NCH2(CH2)2CH2C:— C — OH 
Phenylalanine Alpha-methyl-L 
phenylalanine 
H N 
2 0 
HO 
Phenylalanine p-Arnino-DL-phenylalanine NH; O 
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TABLE A-continued 
Structure of 
Natural Amino Acid Unnatural Amino Acid Unnatural AIHIHO Acid 
Tyrosine 3-Fluoro-L-tyrosine O 
OH 
HZNhI“. 
H 
HO F 
Valine D-Norvaline 
In some embodiments, the polypeptide molecule com 
prises the sequence of a fragment of WtGBP, wherein one or 
more natural amino acids are replaced With one or more 
unnatural amino acids set forth in Table A. In some embodi 
ments, the WtGBP can be from E. coli. In some embodiments, 
the WtGBP can be from T marilima. In some embodiments, 
the WtGBP can be from T lhermophilus. In some embodi 
ments, the polypeptide molecule comprises the sequence of 
SEQ ID NO: 1, Wherein one or more natural amino acids are 
replaced With one or more unnatural amino acids set forth in 
Table A. In some embodiments, the polypeptide molecule 
comprises the sequence of SEQ ID NO: 2, Wherein one or 
more natural amino acids are replaced With one or more 
unnatural amino acids set forth in Table A. In some embodi 
ments, the polypeptide molecule comprises the sequence of 
SEQ ID NO: 3, Wherein one or more natural amino acids are 
replaced With one or more unnatural amino acids set forth in 
Table A. In some embodiments, the polypeptide molecule 
comprises the sequence of SEQ ID NO: 4, Wherein one or 
more natural amino acids are replaced With one or more 
unnatural amino acids set forth in Table A. In some embodi 
ments, the polypeptide molecule comprises the sequence of 
SEQ ID NO: 5, Wherein one or more natural amino acids are 
replaced With one or more unnatural amino acids set forth in 
Table A. In some embodiments, the polypeptide molecule 
comprises the sequence of SEQ ID NO: 6, Wherein one or 
more natural amino acids are replaced With one or more 
unnatural amino acids set forth in Table A. In some embodi 
ments, the polypeptide molecule comprises the sequence of 
SEQ ID NO: 7, Wherein one or more natural amino acids are 
replaced With one or more unnatural amino acids set forth in 
Table A. 
In some embodiments of the presently-disclosed subject 
matter, the isolated polypeptide molecule is an unnatural 
analogue of WtGBP, including one or more of the folloWing 
substitutions: 
(i) at least one alanine is replaced With an unnatural ala 
nine; 
(ii) at least one glycine is replaced With an unnatural gly 
cine; 
(iii) at least one lysine is replaced With an unnatural lysine; 
(iv) at least one phenylalanine is replaced With an unnatural 
phenylalanine; 
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(V) at least one proline is replaced With an unnatural pro 
line; 
(vi) at least one tyrosine is replaced With an unnatural 
tyrosine; 
(vii) at lest one valine is replaced With an unnatural valine; 
(viii) at least one leucine is replaced With an unnatural 
leucine; and 
(ix) at least one tryptophan is replaced With an unnatural 
tryptophan. 
In some embodiment, at least one alanine is replaced With 
an unnatural alanine selected from: 2-Pyridylalanine, 3-Py 
ridylalanine, 4-Pyridylalanine, p-Iodophenylalanine, p-Bro 
mophenylalanine, and L-2-Aminobutyric acid. 
In some embodiment, at least one glycine is replaced With 
an unnatural glycine selected from: L-Allylglycine, L-Prop 
argylglycine, 2-MethoXy-phenylglycine, and 3-Thienylgly 
cine. 
In some embodiments, at least one lysine is replaced With 
D-lysine. 
In some embodiments, at least one phenylalanine is 
replaced With an unnatural phenylalanine selected from: 
Alpha-methyl-L-phenylalanine, and p-Amino-DL-phenyla 
lanine 
In some embodiments, at least one proline is replaced With 
an unnatural proline selected from: alpha-BenZyl-proline 
HCl, and gamma-(3-?uoro-benZyl)-L-proline-HCl. 
In some embodiments, at least one tyrosine is replaced With 
3-Fluoro-L-tyrosine. 
In some embodiments, at least one valine is replaced With 
D-norvaline. 
In some embodiments, at least one leucine is replaced With 
5,5,5-tri?uoro-DL-leucine. 
In some embodiments, at least one tryptophan is replaced 
With an unnatural tryptophan selected from: 5-HydroXy-L 
tryptophan, 5-?uoro-L-tryptophan, 7-aZatryptophan, 6-aZa 
tryptophan, and amino tryptophans. 
In some embodiments, the polypeptide molecule is a 
WtGBP or fragment thereof, Wherein one or more natural 
leucines are replaced With unnatural leucines. Without Wish 
ing to be bound by theory, it is believed that replacing one or 
more natural leucines With unnatural leucines confers 
enhanced thermal and chemical stability to the resulting 
polypeptide analogue. In some embodiments, all natural leu 
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cines are replaced With unnatural leucines. In some embodi 
ments, the unnatural leucines are 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 1, Wherein one or more 
natural leucines are replaced With unnatural leucines. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 1, Wherein one or more natural 
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 1, Wherein all of the natural leucines 
are replaced With 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 2, Wherein one or more 
natural leucines are replaced With unnatural leucines. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 2, Wherein one or more natural 
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 2, Wherein all of the natural leucines 
are replaced With 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 3, Wherein one or more 
natural leucines are replaced With an unnatural leucines. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 3, Wherein one or more natural 
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 3, Wherein all of the natural leucines 
are replaced With 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 4, Wherein one or more 
natural leucines are replaced With an unnatural leucines. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 4, Wherein one or more natural 
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 4, Wherein all of the natural leucines 
are replaced With 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 5, Wherein one or more 
natural leucines are replaced With an unnatural leucines. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 5, Wherein one or more natural 
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 5, Wherein all of the natural leucines 
are replaced With 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 6, Wherein one or more 
natural leucines are replaced With unnatural leucines. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 6, Wherein one or more natural 
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 6, Wherein all of the natural leucines 
are replaced With 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 7, Wherein one or more 
natural leucines are replaced With unnatural leucines. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 7, Wherein one or more natural 
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In 
some embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 7, Wherein all of the natural leucines 
are replaced With 5,5,5-tri?uoro-DL-leucine. 
In some embodiments, the polypeptide molecule is a 
WtGBP or fragment thereof, Wherein one or more natural 
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tryptophans are replaced With unnatural tryptophans. Without 
Wishing to be bound by theory, and With reference to the 
description herein of biomarkers including an isolated 
polypeptide molecule that is capable of emitting a signal 
When binding glucose, it is believed that replacing one or 
more natural tryptophans With unnatural tryptophans confers 
an enhanced ability of the resulting biomarker to emit a sig 
nal, e.g., ?uoresce. For example, as shoWn in FIG. 12, the 
incorporation of 7-AZatryptophan in GRP enhances the inten 
sity of ?uorescence emission. Further, as shoWn in FIG. 13 
the incorporation of 7-AZatryptophan in GRP results in a 
clearly distinguishable ?uorescence signature betWeen 
7-AZatryptophan GRP With and Without bound glucose 
across different temperatures. In some embodiments all natu 
ral tryptophans are replaced With unnatural tryptophans. In 
some embodiments, unnatural tryptophans are selected from: 
5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan. In 
some embodiments, the unnatural tryptophans are 5-?uorot 
ryptophan. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 1, Wherein one or more 
natural tryptophans are replaced With unnatural tryptophans. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 1, Wherein one or more natural 
tryptophans are replaced With unnatural tryptophan selected 
from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 1, Wherein one or more natural 
tryptophans are replaced With 5-?uorotryptophan. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 1, Wherein all of the natural tryp 
tophans are replaced With S-?uorotryptophan. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 2, Wherein one or more 
natural tryptophans are replaced With unnatural tryptophans. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 2, Wherein one or more natural 
tryptophans are replaced With unnatural tryptophan selected 
from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 2, Wherein one or more natural 
tryptophans are replaced With 5-?uorotryptophan. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 2, Wherein all of the natural tryp 
tophans are replaced With 5-?uorotryptophan. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 3, Wherein one or more 
natural tryptophans are replaced With unnatural tryptophans. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 3, Wherein one or more natural 
tryptophans are replaced With unnatural tryptophan selected 
from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 3, Wherein one or more natural 
tryptophans are replaced With 5-?uorotryptophan. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 3, Wherein all of the natural tryp 
tophans are replaced With 5-?uorotryptophan. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 4, Wherein one or more 
natural tryptophans are replaced With unnatural tryptophans. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 4, Wherein one or more natural 
tryptophans are replaced With unnatural tryptophan selected 
from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 4, Wherein one or more natural 
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tryptophans are replaced With 5-?uorotryptophan. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 4, Wherein all of the natural tryp 
tophans are replaced With 5-?uorotryptophan. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 5, Wherein one or more 
natural tryptophans are replaced With unnatural tryptophans. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 5, Wherein one or more natural 
tryptophans are replaced With unnatural tryptophan selected 
from: 5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 5, Wherein one or more natural 
tryptophans are replaced With 5-?uorotryptophan. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 5, Wherein all of the natural tryp 
tophans are replaced With 5-?uorotryptophan. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 6, Wherein one or more 
natural tryptophans are replaced With unnatural tryptophans. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 6, Wherein one or more natural 
tryptophans are replaced With unnatural tryptophan selected 
from: 5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 6, Wherein one or more natural 
tryptophans are replaced With 5-?uorotryptophan. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 6, Wherein all of the natural tryp 
tophans are replaced With 5-?uorotryptophan. 
In some embodiments, the polypeptide molecule com 
prises the sequence of SEQ ID NO: 7, Wherein one or more 
natural tryptophans are replaced With unnatural tryptophans. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 7, Wherein one or more natural 
tryptophans are replaced With unnatural tryptophan selected 
from: 5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan. 
In some embodiments, the polypeptide molecule comprises 
the sequence of SEQ ID NO: 7, Wherein one or more natural 
tryptophans are replaced With 5-?uorotryptophan. In some 
embodiments, the polypeptide molecule comprises the 
sequence of SEQ ID NO: 7, Wherein all of the natural tryp 
tophans are replaced With 5-?uorotryptophan. 
In some embodiments, the polypeptide molecule com 
prises a WtGBP or fragment thereof, Wherein at least one 
natural leucine is replaced With 5,5,5-tri?uoro-DL-leucine, 
and at least one natural tryptophan is replaced With an unnatu 
ral tryptophan selected from 5-hydroxy-L-tryptophan, and 
5-?uoro-L-tryptophan. In some embodiments, at least one 
natural leucine is replaced With 5,5,5-tri?uoro-DL-leucine, 
and at least one natural tryptophan is replaced With 5-?uoro 
L-tryptophan. In some embodiments, all natural leucines are 
replaced With 5 ,5 ,5 -tri?uoro -DL-leucine, and all natural tryp 
tophans are replaced With 5-?uoro-L-tryptophan. 
In some embodiments, When more than one of a particular 
natural amino acid is replaced With an unnatural amino acid, 
different unnatural amino acids can be used. For one example, 
in some embodiments, an unnatural analogue can include a 
?rst natural tryptophan replaced With 5-hydroxy-L-tryp 
tophan, and a second natural tryptophan replaced With 
5-?uoro-L-tryptophan. 
In some embodiments of the presently-disclosed subject 
matter, the isolated polypeptide molecule is an unnatural 
analogue fragment of WtGBP that selectively binds glucose. 
In embodiments Where the polypeptide molecule comprises 
an unnatural analogue fragment of WtGBP, natural amino 
acids can be replaced With unnatural amino acids, as 
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described above With reference to unnatural analogues of 
WtGBP. In some embodiments, the polypeptide molecule 
comprises a fragment of WtGBP, Wherein at least one natural 
amino acid is replaced With an unnatural amino acid, such as 
an unnatural amino acid set forth in Table A. For another 
example, in some embodiments, the polypeptide molecule 
comprises a fragment of SEQ ID NOs: 2, 3, 4, 5, 6, or 7, 
Wherein at least one natural amino acid is replaced With an 
unnatural amino acid, such as an unnatural amino acid set 
forth in TableA. For another example, in some embodiments, 
the polypeptide molecule comprises a fragment of WtGBP 
Wherein at least one leucine is replaced With 5,5,5-tri?uoro 
DL-leucine, and/or at least one tryptophan is replaced With 
5-?uoro-L-tryptophan. In some embodiments, the polypep 
tide molecule comprises a fragment of WtGBP Wherein all 
natural leucines are replaced With 5,5,5-tri?uoro-DL-leucine, 
and/or all natural tryptophans are replaced With 5-?uoro-L 
tryptophan. 
In some embodiments, the isolated polypeptide molecule 
is a fragment, unnatural analogue of WtGBP, or an unnatural 
analogue fragment of WtGBP, Wherein one or more amino 
acids have been added to the N-terminus and/or the C-termi 
nus of the isolated polypeptide molecule. For example, in 
some embodiments, Met-Arg can be added to the N-terminus 
of the isolated polypeptide molecule. For another example, in 
some embodiments, Arg-Ser-His-His-His-His-His-His can 
be added to the C-terminus of the isolated polypeptide mol 
ecule. 
The presently-disclosed subject matter includes a biosen 
sor capable of detecting glucose. As used herein, the term 
“detect” means to determine quantitatively and/or qualita 
tively. The biosensor includes an isolated polypeptide mol 
ecule that is capable of selectively binding glucose, and a 
label capable of generating a signal When the isolated 
polypeptide molecule binds glucose. The isolated polypep 
tide molecule of the biosensor can be an isolated polypeptide 
molecule as described above. The label canbe associated With 
a binding site of the isolated polypeptide molecule, Which 
label is capable of generating a signal. For example, the label 
can be a ?uorescent label, e.g., ?uorophore, or an electro 
chemical label. 
As used herein, the terms “label” and “labeled” refer to the 
attachment of a moiety, capable of detection by spectro 
scopic, radiologic, or other methods, to a probe molecule. 
Thus, the terms “label” or “labeled” refer to incorporation or 
attachment, optionally covalently or non-covalently, of a 
detectable marker into a molecule, such as a polypeptide. 
Various methods of labeling polypeptides are knoWn in the art 
and can be used. Speci?c examples are described herein. 
Fluorescent probes that can be utiliZed include, but are not 
limited to ?uorescein isothiocyanate; ?uorescein dichlorotri 
aZine and ?uorinated analogs of ?uorescein; naphtho?uores 
cein carboxylic acid and its succinimidyl ester; carbox 
yrhodamine 6G; pyridyloxaZole derivatives; Cy2, 3, 3.5, 5, 
5.5, and 7; phycoerythrin; phycoerythrin-Cy conjugates; 
?uorescent species of succinimidyl esters, carboxylic acids, 
isothiocyanates, sulfonyl chlorides, and dansyl chlorides, 
including propionic acid succinimidyl esters, and pentanoic 
acid succinimidyl esters; succinimidyl esters of carboxytet 
ramethylrhodamine; rhodamine Red-X succinimidyl ester; 
Texas Red sulfonyl chloride; Texas Red-X succinimidyl 
ester; Texas Red-X sodium tetra?uorophenol ester; Red-X; 
Texas Red dyes; tetramethylrhodamine; lissamine rhodamine 
B; tetramethylrhodamine; tetramethylrhodamine isothiocy 
anate; naphtho?uoresceins; coumarin derivatives (e. g., 
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hydroxycoumarin, aminocoumarin, and methoxycoumarin); 
pyrenes; pyridyloxazole derivatives; dapoxyl dyes; Cascade 
Blue and Yellow dyes; benzofuran isothiocyanates; sodium 
tetra?uorophenols; 4,4-di?uoro-4-bora-3a,4a-diaza-s-in 
dacene; ALEXA FLUORS® (e.g., 350, 430,488, 532, 546, 
555, 568, 594, 633, 647, 660, 680, 700, and 750); green 
?uorescent protein; yelloW ?uorescent protein; and fruit ?uo 
rescent proteins. The peak excitation and emission Wave 
lengths Will vary for these compounds and selection of a 
particular ?uorescent probe for a particular application can be 
made in part based on excitation and/or emission Wave 
lengths. 
In some embodiments, the isolated polypeptide molecule 
is a fragment, an unnatural analogue, or an unnatural ana 
logue fragment of a WtGBP; and the label is attached to an 
amino acid residue of the isolated polypeptide molecule. The 
label can be attached to one of the folloWing amino acid sites 
close to the binding site of the isolated polypeptide molecule, 
and identi?ed With reference to WtGBP of SEQ ID NO: 1 : Asp 
13,Asp 44, Val 68, Ala 71, Phe 90, Lys 92, Glu 93, Pro 94, Lys 
97, Gly 109, Thr 110, Asp 111, Gly 151, Pro 153, Ala 155, 
Asp 184, Asp 212, Leu 255, Ala 258, Asn 260, Ala 262, Arg 
292, Val 293, and Pro 294. The label can be a ?uorophore, 
such as a ?uorophore selected from: BODIPY 630/650 (Bro 
momethyl); ALEXA FLUORS® 680 679/702 (Maleimide); 
NBD 478/541 (Haloacetamide); PyMPO 415/570 (Haloac 
etamide); Texas Red 595/615 (Maleimide); and MDCC (N 
[2-(1 -maleimidyl(ethyl] -7-(diethylamino)coumarin-3 -car 
boxamide). 
The biosensors of the presently-disclosed subject matter 
can be utilized in a number of different capacities in order to 
detect glucose, both in vitro and in vivo. As one non-limiting 
example, the biosensor can be coupled With a catheter for 
continuous in vivo detection of glucose in a body of a subject. 
Any knoWn catheter suitable for implantation in a body canbe 
utilized With the biosensors disclosed herein, including but 
not limited to catheter systems disclosed in International 
Patent Application No. PCT/US08/732338 to Daunert et al. 
entitled “DEVICE FOR DETECTION OF MOLECULES 
OF INTEREST,” claiming priority from US. Provisional 
Application Ser. Nos. 60/954,269 and 60/954,348, and ?led 
on Aug. 6, 2008 (hereinafter referred to as the “Daunert et al. 
Application), Which is incorporated herein by reference in its 
entirety. 
In addition to coupling With catheter systems, the biosen 
sors disclosed herein can also be utilized in several other 
systems for glucose detection. The incorporation of non 
natural amino acids into single locations Within glucose rec 
ognition peptides can alloW for site-speci?c labeling With 
?uorophores, electrochemical tags, etc., due to the enhanced 
functional diversity that non-natural amino acids have in 
comparison to their canonical counterparts. This site speci?c 
potential provides for greater control and analytical reproduc 
ibility When developing glucose biosensors With non-natural 
glucose recognition peptides. The incorporation of non-natu 
ral amino acids further permits for the site-speci?c immobi 
lization of these glucose recognition peptides, Which can 
decrease the activity loss that is commonly encountered upon 
peptide immobilization. The retention of this glucose respon 
sive activity can be useful in optimizing both hydrogel-cath 
eter based glucose sensors disclosed in the Daunert et al. 
Application and in developing alternative sensor designs. 
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For example, the biosensors disclosed herein comprising 
novel glucose recognition peptides can be employed for the 
development of sensing systems on non-catheter platform 
systems. For example, the biosensors disclosed herein can be 
used to quantitate glucose levels on both microtiter plate and 
miniaturized micro?uidics platforms, Which are popular in 
high-throughput screening, clinical laboratory practice, and 
in the development of point-of-care diagnostic equipment. 
Additionally, presently-disclosed biosensors can be immobi 
lized on affordable and robust paper strips, Whose visible 
color change Would correlate to glucose levels. These paper 
strips Would be a practical and competitive option for patient 
self-monitoring of glucose levels. Moreover, the dynamic 
range of the glucose recognition peptides of the presently 
disclosed subject matter can permit salivary analysis of glu 
cose levels, instead of the painful and invasive ?nger prick 
method commonly used today. 
In addition, the non-natural glucose recognition peptides 
disclosed herein and contained Within hydrogel, as disclosed 
for example in the Daunert et al. Application can also be used 
for the development and improvement implantable drug 
delivery devices and contact lens glucose sensors. As an 
example of a potential use in implantable drug delivery 
devices, the change in ?uorescent or electrical signal caused 
by glucose binding to the appropriately labeled glucose rec 
ognition peptides can be translated to the opening and closing 
of a reversible insulin-containing drug reservoir. In this man 
ner glucose levels can be both monitored and corrected in 
diabetic patients With a glucose responsive glucose recogni 
tion peptide-hydrogel derived device. Additionally, current 
contact lens glucose sensors have a sensing plastic chip incor 
porated into the regular corrective lens. This plastic chip 
changes colors via holographic sensing methods and boron 
containing ?uorophores. These color changes are visible to 
the Wearer, With different colors corresponding to different 
glucose levels in tears, thus alerting the patient if insulin is 
needed. One advantage the biosensors described herein have 
over this current contact lens scheme is that the glucose 
sensor disclosed herein can be hydrogel based. Hydrogels are 
more Water and oxygen permeable than the plastic chips that 
are currently used, and this permeability is quite important for 
both the comfort and long term optical health of the contact 
lens Wearer. 
The presently-disclosed subj ect matter is further illustrated 
by the folloWing speci?c but non-limiting examples. The 
folloWing examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
presently-disclosed subject matter. 
EXAMPLES 
Expression and Labeling of Isolated Polypeptide Mol 
ecules. In order to obtain the gene for insertion into an expres 
sion vector, PCR ampli?cation Was employed. Primers Were 
designed to amplify isolated polypeptide molecules of inter 
est, e.g., polypeptide molecules of SEQ ID NOS: 1-7, and a 
fragment including amino acids 87-271 of SEQ ID NO: 1. 
Table B shoWs data from the fragment containing amino acids 
87-271 from E. coli. This fragment shoWed large error and no 
clear trend in response to glucose, Which demonstrates that 
rational design of truncated forms of WtGBPs is necessary to 
render a responsive glucose recognition peptide. 
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TABLE B 
Glucose Fluorescence 
Concentration Intensity Standard 
(M) (AVG) Deviation 
0 485.282 17.004 
1.00E-08 442.682 32.888 
1.00E-07 463.041 20.018 
1.00E-06 497.146 22.400 
1.00E-05 478.877 36.678 
1.00E-04 467.383 41.020 
1.00E-03 468.792 23.450 
Once the PCR ampli?ed gene fragments Were obtained, 
they Were inserted into expression vector pQE70. The con 
structed expression plasmids Were then transformed into the 
auxotrophic strain of E. coli. Protein expression Was per 
formed using medium shift method. A single freshly trans 
formed colony Was used to inoculate 5 mL of M9 media 
supplemented With 0.4% glucose; 1 mM MgSO4; 0.1 mM 
CaCl2; 1 mM Thiamine; 0.1 volume of a solution containing 
0.01% (W/v) each of 20 amino acids, less any amino acid that 
is to be replaced by unnatural amino acids (e.g., each of 19 
amino acids Where one is to be replaced); 40 ug/mL of the 
remaining amino acid(s) (e.g., 20”’ amino acid), and appro 
priate amount of antibiotic. T his culture Was alloWed to groW 
overnight at 37° C., 250 rpm. 500 mL culture containing the 
same ingredients Was inoculated With the overnight groWn 5 
mL culture. This culture Was then groWn until the optical 
density (OD6OO) Was about 0.5. The cells Were then centri 
fuged at 10000 rpm for 10 min, 250 C., the supernatant Was 
discarded and the cells Were resuspended in a 0.9% NaCl 
solution for Washing, and this Was repeated three times. The 
cells Were then resuspended in 500 mL M9 minimal media 
Which Was supplemented With 0.4% glucose, 1 mM MgSO4, 
0.1 mM CaCl2, 1 mM Thiamine, 0.1 volume of a solution 
containing 0.01% (W/v) each of 20 amino acids less any 
amino acid(s) to be replaced by unnatural amino acids (e.g., 
19 amino acids), appropriate amount of antibiotic, and groWn 
at 37° C. for 30 min to further deplete natural amino acid that 
has to be replaced by the unnatural amino acid. 1 mM IPTG 
Was then added With 0.1 mM of unnatural amino acid to the 
culture and Was groWn overnight at 37° C. The cells Were 
harvested by centrifugation and the protein Was puri?edusing 
Ni-NTA resin since GBP mutant has His-tag. The puri?ed 
protein Was then labeled With ?uorophore MDCC (N-[2-(1 
maleimidyl(ethyl]—7-(diethylamino)coumarin-3-carboxam 
ide), e.g., labeled at cysteine-152 of SEQ ID NO: 1. 
Fragments of WtGBP in Response to Glucose. In order to 
check for activity of the labeled tGBPs, an assay Was per 
formed. Upon glucose binding, the proteins should undergo a 
conformational change, resulting in a change in the local 
environment of the ?uorophore molecule, Which leads to a 
change in the ?uorescence signal observed. The assay Was 
carried out by preparing glucose solutions of concentrations 
ranging from 1><10_lM to 1><10_6M. These glucose standards 
Were then added to 180 pL samples of the labeled tGBPs at a 
concentration of 1><10_7M. The resulting ?uorescence inten 
sity Was measured. The results obtained from one study 
including the isolated polypeptide molecules of SEQ ID NO: 
2 (tGBPl) and SEQ ID NO: 3 (tGBP2) are presented in Table 
C. 
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TABLE c 
Fluorescence signal quenching in response to varying 
concentration of glucose obtained from tGBPs. 
Percent Fluorescence Quenching 
Glucose, M tGBPl tGBP2 
1x 10’6 —0.09539 1.748188 
1 x 10’5 2.907571 2.794934 
1 x 1041 2.432862 5.87441 
1 x 10’3 7.5538 8.966095 
1 x 10’2 14.60875 7.50211 
1 x 10’1 20.36978 6.265703 
Unnatural Analogues of WtGBP With Unnatural Tryp 
tophans. Unnatural analogues of WtGBP from E. coli Were 
produced, Where natural tryptophans Were replaced With 
unnatural tryptophans. Tryptophan auxotrophic strain of E. 
coli (#27873) Was obtained. Plasmid placI and plasmid 
pQE70 containing the genetic sequence of the WtGBP 
mutated at 152 (containing a cysteine in this position for 
?uorophore attachment) Were transformed into the tryp 
tophan auxotrophic strain of E. coli. Protein expression Was 
performed using medium shift method. A single freshly trans 
formed colony Was used to inoculate 5 mL of M9 media 
supplemented With 0.4% glucose, 1 mM MgSO4, 0.1 mM 
CaCl2, 1 mM Thiamine, 0.1 volume of a solution containing 
0.01% (W/v) each of 18 amino acids (less Trp and Leu), 40 
ug/mL Leu, 40 ug/mL Trp, 100 ug/mL Ampicillin, and 35 
ug/mL Chloramphenicol. 
This culture Was alloWed to groW overnight at 37° C., 250 
rpm. 500 mL culture containing the same ingredients Was 
inoculated With the overnight groWn 5 mL culture. This cul 
ture Was then groWn till the optical density (OD6OO) Was about 
0.5. The cells Were then centrifuged at 10000 rpm for 10 min, 
250 C., the supernatant Was discarded and the cells Were 
resuspended in a 0.9% NaCl solution for Washing, and this 
Was repeated three times. The cells Were then resuspended in 
500 mL M9 minimal media Which Was supplemented With 
0.4% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 1 mM Thia 
mine, 0.1 volume of a solution containing 0.01% (W/v) each 
of 18 amino acids (less Trp and Leu), 40 ug/mL Leu, 100 
ug/mL Ampicillin and 35 ug/mL Chloramphenicol, and 
groWn at 37° C. for 30 min to further deplete natural tryp 
tophan. 1 mM IPTG Was then added With 0.1 mM 5-Fluorot 
ryptophan to the culture and Was groWn overnight at 37° C. 
The cells Were harvested by centrifugation and the protein 
Was puri?ed using Ni-NTA resin since the produced mutant 
has a His-tag. The puri?ed protein Was then labeled With 
?uorophore MDCC (N-[2-(1-maleimidyl)ethyl]—7-(diethy 
lamino)coumarin-3-carboxamide). 
Unnatural Analogues of WtGBP With Unnatural Leucines. 
Unnatural analogues of WtGBP from E. coli Were produced, 
Where natural leucines Were replaced With unnatural leucines. 
Leucine auxotrophic strain of E. coli HB101F Was used for 
groWing the glucose recognition protein With unnatural leu 
cines. The procedure for groWing and harvesting the cells Was 
similar to the procedure described above With reference to 
unnatural analogues With unnatural tryptophans, except that 
no Chloramphenicol Was added to the cultures. 
Unnatural Analogues of WtGBP in Response to Glucose. 
Labeled protein Was diluted to 5x10‘7 M and 180 pL of this 
diluted labeled protein Was incubated With 20 pL of different 
concentrations of glucose (10'2 M-10'8 M) for 15 min at 
room temperature. Fluorescence of the samples Was then 
measured using a Carry Eclipse Fluorimeter. 
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FIG. 3 is a dose response curve for glucose With an unnatu 
ral analogue of a WtGBP including unnatural tryptophan. The 
unnatural analogue of WtGBP is the isolated polypeptide of 
SEQ ID NO: 1, Where all natural tryptophans are replaced 
With 5-?uorotryptophans. A dose-dependent change in ?uo 
rescence intensities observed When the unnatural analogue is 
contacted With increasing concentrations of glucose. 
FIG. 4 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP including unnatural tryp 
tophan. The unnatural analogue fragment of WtGBP is the 
isolated polypeptide of SEQ ID NO: 2, Where all natural 
tryptophans are replaced With 5-?uorotryptophans. A dose 
dependent change in ?uorescence intensities observed When 
the unnatural analogue fragment is contacted With increasing 
concentrations of glucose. 
FIG. 5 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP including unnatural tryp 
tophan. The unnatural analogue fragment of WtGBP is the 
isolated polypeptide of SEQ ID NO: 3, Where all natural 
tryptophans are replaced With 5-?uorotryptophans. A dose 
dependent change in ?uorescence intensities observed When 
the unnatural analogue fragment is contacted With increasing 
concentrations of glucose. 
FIG. 6 is a dose response curve for glucose With an unnatu 
ral analogue of a WtGBP including unnatural leucine. The 
unnatural analogue of WtGBP is the isolated polypeptide of 
SEQ ID NO: 1, Where all natural leucines are replaced With 
5,5,5-tri?uoroleucines. A dose-dependent change in ?uores 
cence intensities observed When the unnatural analogue is 
contacted With increasing concentrations of glucose. 
FIG. 7 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP including unnatural leu 
cine. The unnatural analogue fragment of WtGBP is the iso 
lated polypeptide of SEQ ID NO: 2, Where all natural leucines 
are replaced With 5,5,5-tri?uoroleucines. A dose-dependent 
change in ?uorescence intensities observed When the unnatu 
ral analogue fragment is contacted With increasing concen 
trations of glucose. 
FIG. 8 is a dose response curve for glucose With an unnatu 
ral analogue fragment of a WtGBP including unnatural leu 
cine. The unnatural analogue fragment of a WtGBP is the 
isolated polypeptide of SEQ ID NO: 3, Where all natural 
leucines are replaced With 5,5,5-tri?uoroleucines. A dose 
dependent change in ?uorescence intensities observed When 
the unnatural analogue fragment is contacted With increasing 
concentrations of glucose. 
Labeled protein Was immobilized in an acrylamide based 
hydrogel and the hydrogel Was then immobilized on the tip of 
an optical ?ber. The tip of the optical ?ber With immobilized 
hydrogel Was then dipped in glucose solutions of different 
concentration made in 10 mM HEPES, 0.2 mM CaCl2, pH 8.0 
buffer and the change in ?uorescence intensity Was measured 
using an Ocean Optics ?ber optic instrument. FIG. 9 is a dose 
response curve for glucose in buffer With an unnatural ana 
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logue of WtGBP including unnatural tryptophan, immobi 
lized on a ?ber optic tip. A dose-dependent change in ?uo 
rescence intensities observed When the unnatural analogue 
fragment is contacted With increasing concentrations of glu 
cose. 
Circular dichroism (CD) spectra Were obtained to deter 
mine the structural integrity at different temperatures, i.e., 
thermal stability, of an unnatural analogue fragment of a 
WtGBP including unnatural leucines, as compared to a 
WtGBP. FIG. 10 is a circular dichroism spectrum of an 
unnatural analogue fragment of a WtGBP. The unnatural ana 
logue of WtGBP is the isolated polypeptide of SEQ ID NO: 2, 
Where all natural leucines are replaced With 5,5,5-tri?uoro 
leucines. FIG. 11 is a CD spectrum of a WtGBP, including the 
isolated polypeptide of SEQ ID NO: 1. The CD spectrum of 
FIG. 11 shoWs that the WtGBP is stable Within the tempera 
ture range of about 350 C. to about 55° C. The CD spectrum 
of FIG. 10 shoWs that the unnatural analogue including 
unnatural leucines has better thermal stability, shoWing sta 
bility over a Wider range of about 350 C. to about 75° C. 
Method of Detecting Molecules of Interest 
An exemplary method for continuous detection of a mol 
ecule of interest includes initially immersing a tip of an opti 
cal ?ber having a biosensor positioned on said tip into a 
sample. The biosensor includes an isolated peptide having a 
binding site that selectively binds said molecule of interest. 
Upon binding the molecule of interest, the peptide emits a 
signal that is transmitted by said optical ?ber, to thereby 
detect said molecule of interest. The method further includes 
collecting the signal With a detection and data collection 
device operably connected With the optical ?ber and then 
correlating the signal to an amount of the molecule of interest. 
The amount of the molecule of interest can then be displayed. 
In some embodiments, the molecule of interest can be glucose 
or IL-6, and the biosensor peptide can be a glucose binding 
protein or an IL-6-speci?c antibody, respectively. 
In this exemplary embodiment, the peptide has high stabil 
ity at physiological conditions and is incorporated Within an 
optically transparent hydrogel positioned on said distal tip. 
The biosensor includes a label associated With the binding 
site. The label generates the signal and is selected from a 
?uorescent label and an electrochemical label. 
When the molecule of interest is glucose, the hydrogel can 
include a precursor solution of bisacrylamide, acrylamide, 
buffer solution, glycerol, glucose binding protein, acrylic 
acid, and 2,2-Diethoxyacetaphenone. The precursor solution 
can be UV polymerized for approximately 30 minutes to form 
the hydrogel incorporated With the peptide. 
Finally, the sample can be a blood stream or body ?uid in a 
body of a subject, in vivo, or can be an in vitro sample. 
It Will be understood that various details of the presently 
disclosed subject matter can be changed Without departing 
from the scope of the subject matter disclosed herein. Fur 
thermore, the foregoing description is for the purpose of 
illustration only, and not for the purpose of limitation. 
SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 309 
TYPE: PRT 
ORGANISM: E. Coli 
<400> SEQUENCE: l 




